Pfizer’s Drugs Enter Third Medicare Negotiation Cycle, Gains Three-Year Section 232 Exemption
CMS named Pfizer’s branded drugs for the third Medicare Drug Price Negotiation cycle, including products newly reimbursed under Medicare Part B. Pfizer secured a three-year carve-out from Section 232 price-parity rules and could boost margins if PBM rebate mandates are eliminated.
1. Medicare Selects Pfizer Drugs for Price Negotiation
The Centers for Medicare & Medicaid Services has added three Pfizer-branded products to the third cycle of its Drug Price Negotiation Program, including the company’s rheumatoid arthritis treatment (a self-administered monoclonal antibody reimbursed under Part B) and two specialty oncology agents. These products join a total of 15 branded therapies named this round, marking Pfizer’s first inclusion of Part B-reimbursed medicines in the program. Industry analysts estimate that Medicare negotiations could drive average net price cuts of 25–35% on these drugs, potentially shaving more than $1.2 billion off Medicare Part B expenditures over the next five years.
2. Q4 Earnings Set to Reflect COVID-19 Declines
Consensus forecasts project Pfizer’s fourth-quarter revenues to fall approximately 18% year-over-year, with EPS of roughly $0.68 versus $0.82 a year earlier, as sales of the company’s COVID-19 vaccine and antiviral treatments continue their post-pandemic descent. Excluding pandemic product lines, core revenues are expected to grow low‐single digits, driven by demand for the pneumococcal vaccine and its pneumococcal-conjugate franchise. Management has guided that 2025 R&D spend will rise by around 10% to support late‐stage oncology and rare disease candidates, while operating margins are forecast to compress by 150 basis points due to increased clinical trial costs.
3. Regulatory Carve-Out and Volume Upside Bolster Bullish View
Despite headline risks from proposed global price parity rules under the Great Healthcare Plan, Pfizer secured a negotiated three-year carve-out from Section 232 import tariffs on its core biologics, shielding its margin structure through 2028. Furthermore, the impending launch of TrumpRx.gov is expected to expand patient access to lower-cost generics and biosimilars, which Pfizer anticipates will boost overall prescription volumes for its established vaccine and hospital portfolios by 5–7% annually. Analysts note that the combination of tariff protection and volume leverage could offset up to $200 million in annual rebate pressure, reinforcing a bullish stance even with looming patent expirations on key products scheduled between 2026 and 2028.